Cannabis biotech Creso is set to introduce its hemp-based cannabidiol nutraceuticals to the UK under a new commercialisation agreement announced today.

Cannabidiol (or CBD) is one of the active ingredients (or cannabinoids) — found in cannabis. It has well-researched medicinal benefits — but unlike another cannabinoid, tetrahydrocannabinol (THC), it doesn’t get you high.

The deal with Precision Healthcare will see Creso Pharma’s (ASX:CPH) cannaQIX®10 and 50 nutraceutical products rolled out in the first quarter, targeting pharmacies and health food stores in the UK.

CannaQIX® is a unique standardised nutraceutical product, in a proprietary delivery formulation, that contains full plant organic hemp extract with cannabidiol, vitamins and zinc, aiming to reduce stress and to support mental and nervous functions in humans.

Creso Pharma is well -placed to take advantage of the booming cannabis market, says co-founder Dr Miri Halperin Wernli.
Creso Pharma is well-placed to take advantage of the booming cannabis market, says CEO and Co-Founder Dr Miri Halperin Wernli.

Nutraceuticals – a combination of nutrition and pharmaceuticals – are concentrated sources of nutrients with a nutritional and physiological effect designed to supplement a normal diet.

Under the agreement, Precision Health will market and distribute the CannaQIX® products, already a leading service provider to international pharmaceutical and healthcare companies.

This commercialisation agreement follows confirmation from the UK Trading Standard Office (TSO) for CannaQIX® as a food supplement that can be purchased without the need for a prescription.

Swiss regulatory authorities have issued a Certificate of Free Sale for the export of the product into the UK from Switzerland.

“We are delighted to partner with Precision Healthcare and to have obtained the necessary regulatory approvals for cannaQIX® in the UK – both significant milestones for our company,” said Creso Pharma CEO and Co-Founder, Dr Miri Halperin Wernli.

The cannaQIX® range is produced in Switzerland by Creso’s partner Swiss-based food and pharma development company Domaco to the highest Swiss quality with a “Swiss Made” label.

Commercialisation of Creso’s CBD nutraceutical products follows its new hemp beer venture with Baltic Beer Company and LGC Capital.


This special report is brought to you by Creso Pharma.

This advice has been prepared without taking into account your objectives, financial situation or needs. You should, therefore, consider the appropriateness of the advice, in light of your own objectives, financial situation or needs, before acting on the advice.

If this advice relates to the acquisition, or possible acquisition, of a particular financial product, the recipient should obtain a Product Disclosure Statement (PDS) relating to the product and consider the PDS before making any decision about whether to acquire the product.